tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

INNMF Stock Latest News

Amplia Therapeutics Reports Promising Trial Results for Pancreatic Cancer Drug
Company AnnouncementsAmplia Therapeutics Reports Promising Trial Results for Pancreatic Cancer Drug
8d ago
Amplia Therapeutics Receives FDA Support for Pancreatic Cancer Trial
PremiumCompany Announcements
Amplia Therapeutics Receives FDA Support for Pancreatic Cancer Trial
15d ago
Amplia Therapeutics Issues New Equity Securities
PremiumCompany Announcements
Amplia Therapeutics Issues New Equity Securities
25d ago
Amplia Therapeutics Expands U.S. Market Presence with OTCQB Listing
PremiumCompany Announcements
Amplia Therapeutics Expands U.S. Market Presence with OTCQB Listing
1M ago
Amplia Therapeutics Advances Narmafotinib Trials with Promising Results
PremiumCompany Announcements
Amplia Therapeutics Advances Narmafotinib Trials with Promising Results
1M ago
Amplia Therapeutics Secures $3.77 Million R&D Tax Rebate to Boost Cancer Trials
PremiumCompany AnnouncementsAmplia Therapeutics Secures $3.77 Million R&D Tax Rebate to Boost Cancer Trials
1M ago
Amplia Therapeutics’ Promising Study on Narmafotinib for Pancreatic Cancer
Premium
Company Announcements
Amplia Therapeutics’ Promising Study on Narmafotinib for Pancreatic Cancer
1M ago
INNMF
Amplia Therapeutics Expands U.S. Presence with New Investor Campaign
Premium
Company Announcements
Amplia Therapeutics Expands U.S. Presence with New Investor Campaign
2M ago
Amplia Therapeutics Reports Positive Results in Pancreatic Cancer Trial
PremiumCompany Announcements
Amplia Therapeutics Reports Positive Results in Pancreatic Cancer Trial
2M ago
Amplia Therapeutics Announces Cessation of Securities
PremiumCompany Announcements
Amplia Therapeutics Announces Cessation of Securities
2M ago
Amplia Therapeutics Secures Key US Patent for Cancer Drug Narmafotinib
PremiumCompany Announcements
Amplia Therapeutics Secures Key US Patent for Cancer Drug Narmafotinib
2M ago
Amplia Therapeutics Announces Director’s Interest Changes
PremiumCompany Announcements
Amplia Therapeutics Announces Director’s Interest Changes
3M ago
Amplia Therapeutics Updates Director’s Interest Notice
PremiumCompany AnnouncementsAmplia Therapeutics Updates Director’s Interest Notice
3M ago
Amplia Therapeutics Updates Director’s Interest Notice
Premium
Company Announcements
Amplia Therapeutics Updates Director’s Interest Notice
3M ago
Amplia Therapeutics Updates Director’s Interest Notice
Premium
Company Announcements
Amplia Therapeutics Updates Director’s Interest Notice
3M ago
Amplia Therapeutics Announces Cessation of Securities
PremiumCompany Announcements
Amplia Therapeutics Announces Cessation of Securities
3M ago
Amplia Therapeutics Begins New Pancreatic Cancer Trial with First Patient Dosed
PremiumCompany Announcements
Amplia Therapeutics Begins New Pancreatic Cancer Trial with First Patient Dosed
3M ago
Amplia Therapeutics Announces Cessation of Securities
PremiumCompany Announcements
Amplia Therapeutics Announces Cessation of Securities
3M ago
Amplia Therapeutics’ FAK Inhibitor Gains USAN Approval
PremiumCompany Announcements
Amplia Therapeutics’ FAK Inhibitor Gains USAN Approval
3M ago
Amplia Therapeutics Issues New Unquoted Equity Securities
PremiumCompany AnnouncementsAmplia Therapeutics Issues New Unquoted Equity Securities
3M ago
Amplia Therapeutics Advances Cancer Treatment with Successful Capital Raise
Premium
Company Announcements
Amplia Therapeutics Advances Cancer Treatment with Successful Capital Raise
3M ago
Amplia Therapeutics Announces Quotation of New Securities on ASX
Premium
Company Announcements
Amplia Therapeutics Announces Quotation of New Securities on ASX
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >